96 Tests PN: B113531

Components:

45x Ab-conjugated beads (S5P10 - human CTGF/CCN2/IGFBP-8 -bead). PN: B113531A. One vial containing 100 µL of anti-human CTGF/CCN2/IGFBP-8 conjugated to AimPlex Bead S5P10.

25x Biotin-detection Ab (human CTGF/CCN2/IGFBP-8 Biotin-dAb). PN: B113531B. One vial containing 100 µL of biotinylated anti-human CTGF/CCN2/IGFBP-8.

Lyophilized Standard - Human CTGF/CCN2/IGFBP-8. PN: B113531S. One vial containing lyophilized CTGF/CCN2/IGFBP-8.


Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

Application: Optimal antibody pair and antigen standard for assaying human CTGF/CCN2/IGFBP-8. To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 5 pg/mL

  • Quantitation range:

  • LLOQ: < 15 pg/mL

  • ULOQ: > 5,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Sample volume: 15 µL/test

Description:

CTGF, also known as CCN2 or connective tissue growth factor, has important roles in many biological processes, including cell adhesion, migration, proliferation, angiogenesis, skeletal development, and tissue wound repair, and is critically involved in fibrotic disease and several forms of cancers. In addition to fibrosis, aberrant CTGF expression is also associated with many types of malignancies, diabetic nephropathy and retinopathy, arthritis, and cardiovascular diseases.

References:

1.    Jun JI, et al. Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat Rev Drug Discov. 2011, 10 (12): 945–63. doi:10.1038/nrd3599. PMC 3663145. PMID 22129992.

2.    Chen CC, et al. Functions and mechanisms of action of CCN matricellular proteins. Int. J. Biochem. Cell Biol. 2009, 41 (4): 771–83. doi:10.1016/j.biocel.2008.07.025. PMC 2668982. PMID 18775791.